Allogene Therapeutics (NASDAQ:ALLO) will collaborate with Stanford University to investigate a novel nucleic acid delivery system developed by Stanford researchers to more effectively and safely deliver intracellular RNA or DNA into certain immune cells.
The company plans to explore the technology for potential use in AlloCAR T therapy.
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.